S&P Futures
5,903.25 -2.75 (-0.05%) Dow Futures
43,533.00 +15.00 (+0.03%) Nasdaq Futures
20,454.25 -29.25 (-0.14%) Russell 2000 Futures
2,292.40 +1.20 (+0.05%) Crude Oil
69.64 +0.42 (+0.61%) Gold
2,741.40 +11.40 (+0.42%)
Medigene AG (MDG1.F)
| Previous Close | 1.8620 |
| Open | 1.9020 |
| Bid | 0.0000 x 60700 |
| Ask | 0.0000 x 58600 |
| Day's Range | 1.8920 - 1.9020 |
| 52 Week Range | 1.6000 - 5.3869 |
| Volume | |
| Avg. Volume | 915 |
| Market Cap | 28.274M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2100 |
| Earnings Date | Oct 24, 2024 - Oct 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireMedigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented a universal detection system for 3S (specific, sensitive, and safe) recombinant TCRs (rTCRs), UniTope & TraCR, at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. The presented p
- GlobeNewswire
Medigene to Present at Upcoming Scientific Conferences
Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present at the 16th Annual Protein & Antibody Engineering Summit (PEGS) to be held from November 5-7, 2024 in Barcelona as well as at the Cell 2024 conference by Oxford Global from November 6-8, 2024 in London. In addition, two posters will be pres
